AI Portfolio Summary
In 2025 Q4, Davern Capital Partners, LP maintained a portfolio of 14 distinct positions. The most significant new addition to the portfolio was PFIZER INC, which now represents 16.44% of the total fund value.
Total Positions
14
Quarter
2025 Q4
Top Holding
PFE (16.4%)
Top 10 Concentration
90.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-14 of 14
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PFE
PFIZER INC
|
Unknown | 16.44% | — |
#1
Prev: #—
|
9.5 | 2,042,242 | no change |
NEW
|
2,042,242 | $50,851,826 |
$24.49
+1.1%
|
2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
REGN
REGENERON PHARM...
|
Unknown | 13.08% | — |
#2
Prev: #—
|
9.0 | 52,420 | no change |
NEW
|
52,420 | $40,461,425 |
$770.94
-1.1%
|
2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
BNTX
BIONTECH SE
|
Unknown | 11.43% | — |
#3
Prev: #—
|
8.5 | 371,216 | no change |
NEW
|
371,216 | $35,339,763 |
$95.20
+1.7%
|
2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
RPRX
ROYALTY PHARMA ...
|
Unknown | 10.50% | — |
#4
Prev: #—
|
8.0 | 840,650 | no change |
NEW
|
840,650 | $32,482,716 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE
|
Unknown | 9.70% | — |
#5
Prev: #—
|
7.9 | 35,685 | no change |
NEW
|
35,685 | $30,009,301 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LEGN
LEGEND BIOTECH ...
|
Unknown | 7.43% | — |
#6
Prev: #—
|
6.5 | 1,056,668 | no change |
NEW
|
1,056,668 | $22,971,962 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Unknown | 7.21% | — |
#7
Prev: #—
|
6.4 | 1,028,298 | no change |
NEW
|
1,028,298 | $22,314,067 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Unknown | 6.10% | — |
#8
Prev: #—
|
5.9 | 238,477 | no change |
NEW
|
238,477 | $18,865,915 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Unknown | 5.83% | — |
#9
Prev: #—
|
5.8 | 78,650 | no change |
NEW
|
78,650 | $18,017,929 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Unknown | 2.89% | — |
#10
Prev: #—
|
4.7 | 8,307 | no change |
NEW
|
8,307 | $8,927,367 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Unknown | 2.63% | — |
#11
Prev: #—
|
4.6 | 261,615 | no change |
NEW
|
261,615 | $8,141,459 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Unknown | 2.47% | — |
#12
Prev: #—
|
4.5 | 210,648 | no change |
NEW
|
210,648 | $7,644,416 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Unknown | 2.17% | — |
#13
Prev: #—
|
4.4 | 162,005 | no change |
NEW
|
162,005 | $6,726,448 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Unknown | 2.11% | — |
#14
Prev: #—
|
4.3 | 48,502 | no change |
NEW
|
48,502 | $6,540,737 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-14 of 14 holdings